Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M. Dummer R, et al. Among authors: richtig e. J Clin Oncol. 2023 Aug 10;41(23):3917-3929. doi: 10.1200/JCO.22.02199. Epub 2023 Jun 12. J Clin Oncol. 2023. PMID: 37307514 Clinical Trial.
Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey.
Richtig G, Richtig M, Hoetzenecker W, Saxinger W, Lange-Asschenfeldt B, Steiner A, Strohal R, Posch C, Bauer JW, Müllegger RR, Deinlein T, Sepp N, Volc-Platzer B, Nguyen VA, Schmuth M, Hoeller C, Pregartner G, Richtig E. Richtig G, et al. Among authors: richtig e, richtig m. Acta Derm Venereol. 2019 Jan 1;99(1):58-62. doi: 10.2340/00015555-3037. Acta Derm Venereol. 2019. PMID: 30206639 Free article.
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, Aedo-Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Hoeller C. Ressler JM, et al. Among authors: richtig e. J Immunother Cancer. 2021 Feb;9(2):e001701. doi: 10.1136/jitc-2020-001701. J Immunother Cancer. 2021. PMID: 33608376 Free PMC article.
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
Usage and benefit of the Internet as a source of information on disease and therapy in dermatology.
Grossschaedl K, Vallant C, Dernoscheg MT, Richtig M, Öllinger A, Balakirski G, Wilsmann-Theis D, Nguyen VA, Weinlich G, Tsiogka A, Koelblinger P, Scheffel J, Richtig E, Richtig G. Grossschaedl K, et al. Among authors: richtig e. J Dtsch Dermatol Ges. 2023 Nov;21(11):1383-1386. doi: 10.1111/ddg.15199. Epub 2023 Oct 9. J Dtsch Dermatol Ges. 2023. PMID: 37811739 No abstract available.
140 results